Shanghai Shen Lian Biomedical Corporation (SHA:688098)
7.34
+0.12 (1.66%)
Nov 5, 2026, 3:00 PM CST
SHA:688098 Revenue
Shanghai Shen Lian Biomedical had revenue of 79.32M CNY in the quarter ending September 30, 2026, a decrease of -31.60%. This brings the company's total for the last twelve months to 241.82M, down -17.41% year-over-year. In the year 2025, Shanghai Shen Lian Biomedical had annual revenue of 288.27M, down -4.99%. That makes Shanghai Shen Lian Biomedical the 30,140th largest company in the world by revenue and 4,959th in China.
Revenue (ttm)
241.82M
Revenue Growth
-17.41%
P/S Ratio
12.46
Revenue / Employee
643.13K
Employees
376
Market Cap
3.01B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 288.27M | -15.15M | -4.99% |
| Dec 31, 2024 | 303.41M | 1.93M | 0.64% |
| Dec 31, 2023 | 301.49M | -27.11M | -8.25% |
| Dec 31, 2022 | 328.59M | -29.83M | -8.32% |
| Dec 31, 2021 | 358.43M | 20.70M | 6.13% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Xiangxue Pharmaceutical | 1.51B |
| Qingdao Vland Biotech INC. | 1.45B |
| Kexing Biopharm | 1.30B |
| Beijing Kawin Technology Share-Holding | 1.21B |
| Hubei Goto Biopharm Group | 665.71M |
| Zhejiang Shouxiangu Pharmaceutical | 590.94M |
| Lifecome Biochemistry | 453.12M |
| Guanhao Biotech | 344.85M |